Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50
mg/d), administered for 12 weeks, on patients with mild Thyroid-Associated Ophthalmopathy
(TAO).